Biomarkers of interferon beta therapy in multiple sclerosis

Jerome J. Graber, Suhayl Dhib-Jalbut

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Multiple sclerosis (MS) is characterized by episodes of inflammatory damage to myelin and oligodendrocytes in the central nervous system mediated by T, B, and Natural killer lymphocytes of various types, antibody and complement, dendritic cells, macrophages, microglia, and secreted cytokines and chemokines. These relapses cause significant neurologic dysfunction, which is only partially reversible, and eventual secondary progressive neurologic decline frequently occurs. Interferon-beta (IFNβ) has been a mainstay of MS treatment for more than 20 years after being proven to reduce relapse frequency and development of new lesions on magnetic resonance imaging. However, patient response is highly variable and the exact mechanisms of action are not fully understood. Breakthrough relapses and secondary progressive neurologic decline remain significant concerns in long-term MS treatment. Biomarkers may help elucidate the beneficial effects of IFNβ in MS and possibly guide therapeutic decision making given the variety of different therapies now available with varying mechanisms of action and risks. Various serum and cerebrospinal fluid candidate biomarkers have been described, but none have yet been proven to carry sufficient predictive reliability for routine clinical use.

Original languageEnglish (US)
Pages (from-to)600-604
Number of pages5
JournalJournal of Interferon and Cytokine Research
Volume34
Issue number8
DOIs
StatePublished - Aug 1 2014

Fingerprint

Interferon-beta
Multiple Sclerosis
Biomarkers
Recurrence
Nervous System
Oligodendroglia
Microglia
Therapeutics
Myelin Sheath
Neurologic Manifestations
Chemokines
Dendritic Cells
Cerebrospinal Fluid
Decision Making
Central Nervous System
Macrophages
Magnetic Resonance Imaging
Lymphocytes
Cytokines
Antibodies

ASJC Scopus subject areas

  • Immunology
  • Virology
  • Cell Biology
  • Medicine(all)

Cite this

Biomarkers of interferon beta therapy in multiple sclerosis. / Graber, Jerome J.; Dhib-Jalbut, Suhayl.

In: Journal of Interferon and Cytokine Research, Vol. 34, No. 8, 01.08.2014, p. 600-604.

Research output: Contribution to journalArticle

Graber, Jerome J. ; Dhib-Jalbut, Suhayl. / Biomarkers of interferon beta therapy in multiple sclerosis. In: Journal of Interferon and Cytokine Research. 2014 ; Vol. 34, No. 8. pp. 600-604.
@article{7e99a0942459428f80a604a2762c43c2,
title = "Biomarkers of interferon beta therapy in multiple sclerosis",
abstract = "Multiple sclerosis (MS) is characterized by episodes of inflammatory damage to myelin and oligodendrocytes in the central nervous system mediated by T, B, and Natural killer lymphocytes of various types, antibody and complement, dendritic cells, macrophages, microglia, and secreted cytokines and chemokines. These relapses cause significant neurologic dysfunction, which is only partially reversible, and eventual secondary progressive neurologic decline frequently occurs. Interferon-beta (IFNβ) has been a mainstay of MS treatment for more than 20 years after being proven to reduce relapse frequency and development of new lesions on magnetic resonance imaging. However, patient response is highly variable and the exact mechanisms of action are not fully understood. Breakthrough relapses and secondary progressive neurologic decline remain significant concerns in long-term MS treatment. Biomarkers may help elucidate the beneficial effects of IFNβ in MS and possibly guide therapeutic decision making given the variety of different therapies now available with varying mechanisms of action and risks. Various serum and cerebrospinal fluid candidate biomarkers have been described, but none have yet been proven to carry sufficient predictive reliability for routine clinical use.",
author = "Graber, {Jerome J.} and Suhayl Dhib-Jalbut",
year = "2014",
month = "8",
day = "1",
doi = "10.1089/jir.2013.0144",
language = "English (US)",
volume = "34",
pages = "600--604",
journal = "Journal of Interferon and Cytokine Research",
issn = "1079-9907",
publisher = "Mary Ann Liebert Inc.",
number = "8",

}

TY - JOUR

T1 - Biomarkers of interferon beta therapy in multiple sclerosis

AU - Graber, Jerome J.

AU - Dhib-Jalbut, Suhayl

PY - 2014/8/1

Y1 - 2014/8/1

N2 - Multiple sclerosis (MS) is characterized by episodes of inflammatory damage to myelin and oligodendrocytes in the central nervous system mediated by T, B, and Natural killer lymphocytes of various types, antibody and complement, dendritic cells, macrophages, microglia, and secreted cytokines and chemokines. These relapses cause significant neurologic dysfunction, which is only partially reversible, and eventual secondary progressive neurologic decline frequently occurs. Interferon-beta (IFNβ) has been a mainstay of MS treatment for more than 20 years after being proven to reduce relapse frequency and development of new lesions on magnetic resonance imaging. However, patient response is highly variable and the exact mechanisms of action are not fully understood. Breakthrough relapses and secondary progressive neurologic decline remain significant concerns in long-term MS treatment. Biomarkers may help elucidate the beneficial effects of IFNβ in MS and possibly guide therapeutic decision making given the variety of different therapies now available with varying mechanisms of action and risks. Various serum and cerebrospinal fluid candidate biomarkers have been described, but none have yet been proven to carry sufficient predictive reliability for routine clinical use.

AB - Multiple sclerosis (MS) is characterized by episodes of inflammatory damage to myelin and oligodendrocytes in the central nervous system mediated by T, B, and Natural killer lymphocytes of various types, antibody and complement, dendritic cells, macrophages, microglia, and secreted cytokines and chemokines. These relapses cause significant neurologic dysfunction, which is only partially reversible, and eventual secondary progressive neurologic decline frequently occurs. Interferon-beta (IFNβ) has been a mainstay of MS treatment for more than 20 years after being proven to reduce relapse frequency and development of new lesions on magnetic resonance imaging. However, patient response is highly variable and the exact mechanisms of action are not fully understood. Breakthrough relapses and secondary progressive neurologic decline remain significant concerns in long-term MS treatment. Biomarkers may help elucidate the beneficial effects of IFNβ in MS and possibly guide therapeutic decision making given the variety of different therapies now available with varying mechanisms of action and risks. Various serum and cerebrospinal fluid candidate biomarkers have been described, but none have yet been proven to carry sufficient predictive reliability for routine clinical use.

UR - http://www.scopus.com/inward/record.url?scp=84905367120&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84905367120&partnerID=8YFLogxK

U2 - 10.1089/jir.2013.0144

DO - 10.1089/jir.2013.0144

M3 - Article

C2 - 25084176

AN - SCOPUS:84905367120

VL - 34

SP - 600

EP - 604

JO - Journal of Interferon and Cytokine Research

JF - Journal of Interferon and Cytokine Research

SN - 1079-9907

IS - 8

ER -